Loading patent…
AssigneeThe Green Cross Corporation
InventorsHyun-Ja NAM, Sung Ho HWANG, Heechun KWAK, Gahee CHOI, Suyong KIM, Yu Young KIM, Yongmin LEE, Chae Mok LEE, Sunhye SHIN, Young Eun KWON, Seunghyun JO
Estimating the term…
An ADAMTS13 mutant protein having an improved escaping rate against an autoantibody and a composition that is suitable for preventing or treating thrombotic diseases are disclosed. By efficiently avoiding autoantibodies known to have high binding affinity to the main domain of ADAMTS13, the ADAMTS13 variant protein of the present invention can be used as an effective therapeutic composition for various thrombotic diseases, such as TTP (thrombotic thrombocytopenic purpura), in which the presence of such autoantibodies is the main etiology, and can stably maintain the biological activity thereof when administered into a body. In addition, a newly identified site within ADAMTS13, which is recognized by an autoantibody can be used in screening novel ADAMTS13 variants having an improved autoantibody escaping rate by applying a combination of various mutations within the corresponding site.
An ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) variant protein comprising substitutions of one or more amino acid residues selected from the group consisting of the 85th, 93rd, 126th, 135th, 278th, 282nd, 308th, 314th, 317th, 334th, 364th, 376th, 413rd, 427th, 452nd, 465th, 567th, 578th, 585th, 589th, 607th, 608th, 609th, 612th, 618th, 624th, 630th, 635th, 643rd, 650th, 651st, 654th, 655th, 656th, 658th, 664th, and 672nd residues of SEQ ID NO:
-11. (canceled)
A method for screening ADAMTS13 variant with an improved escaping rate for autoantibodies, comprising the following steps of:
Dependencies are inferred from the claim text.